Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Trial Profile

Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms JMIG; PROCLAIM
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Oct 2016 Results from post-hoc subgroup analyses based on positron emission tomography (PET) scan use in non-small cell lung cancer patients presented at the 41st European Society for Medical Oncology Congress.
    • 07 Jun 2016 Results (n=555) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 25 Jan 2016 Primary endpoint has not been met. (Overall survival), as per an article published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top